Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.5
USERS' SCORE
Moderately Good
Based on 8 Reviews
7.7
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Vitamin D3 (as cholecalciferol)
125 mcg
625%
Vitamin K activity from:Vitamin K1 (as phytonadione)Vitamin K2 (as menaquinone-4)Vitamin K2 (as trans menaquinone-7)
2,100 mcg1,000 mcg1,000 mcg100 mcg
1,750%
Iodine [from Sea-Iodine™ Complex Blend (organic kelp and bladderwrack extracts, potassium iodide)]
1,000 mcg
667%
Top Medical Research Studies
8
We investigated the potential of vitamin D3, also known as cholecalciferol, in combating cancer while addressing concerns about its toxicity at higher doses. This study focused on enhancing the effectiveness of vitamin D3 through a clever method called liposomal encapsulation, which helps minimize side effects.
We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.
Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.
We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.
We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.
Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.
We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.
Read More
9
Vitamin D3 derivatives improve cancer treatment
We focused on how modified forms of vitamin D3 can positively affect cancer treatment. The study revealed that a specific derivative, known as MART-10, demonstrated significant anti-tumor effects in mouse models. When administered at low doses, this compound showed robust anti-cancer activity against BxpC-3 cancer cells.
Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.
Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.
Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.
Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.
Read More
9
Iodine treatment aids recurrent cancer
We observed a compelling case where a biodegradable hydrogel spacer was used alongside iodine-125 brachytherapy to treat recurrent prostate cancer. This innovative approach involved placing the spacer to create space between the prostate and the rectum, which significantly reduced radiation exposure to healthy tissues during the treatment.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Read More
Most Useful Reviews
9
Supports immunity enhancement
This is one of the best manufacturers of vitamin D. It promotes muscle tone, increases immunity, supports thyroid function and normal blood clotting, and aids in restoring the protective sheaths around nerves. It also regulates blood pressure and heart rate while preventing cancer cell growth. I recommend taking it year-round at a dosage of 1000, ensuring sufficient levels in the body. Remember, vitamin D has a cumulative effect, so there's no fear of overdose when paired with vitamin K, which reduces liver strain.
Read More
7.5
Reduces cancer growth
Vitamin D helps the body absorb calcium and phosphorus, essential for bone growth. Besides its building function, it performs a protective role by decreasing cancer cell growth, aiding the immune system against infections, and lessening inflammation. It is also crucial for the normal functioning of the neuromuscular, endocrine, and immune systems.
Read More
7.5
Effective for cancer
I have been using this as part of my regimen for cancer treatment, and so far, everything is going well. My vitamin D levels have improved after years of consistent use, proving effective for my health regime.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.5
- All Researches
9
Vitamin D3 derivatives improve cancer treatment
We focused on how modified forms of vitamin D3 can positively affect cancer treatment. The study revealed that a specific derivative, known as MART-10, demonstrated significant anti-tumor effects in mouse models. When administered at low doses, this compound showed robust anti-cancer activity against BxpC-3 cancer cells.
Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.
Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.
Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.
Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.
Read More
9
We explored the potential of iodinated copper-cysteamine (Cu-Cy-I) nanoparticles to enhance cancer treatment when combined with X-ray therapy. The study specifically focused on how these nanoparticles could improve the effectiveness of radiotherapy by increasing the generation of reactive oxygen species (ROS) in tumor cells. This increase in ROS leads to more significant DNA damage in cancer cells, making them more susceptible to radiation treatment.
Our findings revealed that when 4T1 tumor cells were treated with Cu-Cy-I nanoparticles alongside X-ray irradiation, there was a notable improvement in tumor cell killing compared to X-ray treatment alone. Additionally, in mouse models with breast carcinoma, the combination treatment led to better tumor growth inhibition and extended survival time for the mice.
However, we acknowledge that the effectiveness of the iodine component in the nanoparticles at lower doses was not verified in this study. The results suggest that Cu-Cy-I nanoparticles have promise as radiosensitizers in cancer therapy, but more research is needed, particularly regarding the synthesis of smaller nanoparticles for further evaluation.
Our findings revealed that when 4T1 tumor cells were treated with Cu-Cy-I nanoparticles alongside X-ray irradiation, there was a notable improvement in tumor cell killing compared to X-ray treatment alone. Additionally, in mouse models with breast carcinoma, the combination treatment led to better tumor growth inhibition and extended survival time for the mice.
However, we acknowledge that the effectiveness of the iodine component in the nanoparticles at lower doses was not verified in this study. The results suggest that Cu-Cy-I nanoparticles have promise as radiosensitizers in cancer therapy, but more research is needed, particularly regarding the synthesis of smaller nanoparticles for further evaluation.
Read More
9
Iodine enhances lung cancer treatment
We conducted a retrospective study focusing on patients with driver gene-negative non-small cell lung cancer (NSCLC) to explore the effectiveness of iodine-125 (I) seed implantation when paired with immune checkpoint inhibitors (ICIs) and chemotherapy (CT). In our analysis of 95 patients, we compared two groups: one treated with I seed implantation alongside ICIs and CT, and the other treated with conventional radiotherapy (RT) with the same additional therapies.
Our primary goal was to assess the median progression-free survival (mPFS), alongside secondary outcomes that included the one- and two-year progression-free survival rates, as well as the occurrence of adverse events related to treatments. The results were promising: patients who received iodine treatment experienced longer survival times and reported fewer adverse effects compared to those undergoing traditional RT.
The findings suggest that Iodine-125 seed implantation could be a more advantageous option for treating this specific type of lung cancer, offering a precision approach that minimizes damage to healthy lung tissue. This less invasive method could provide patients with a better quality of life while still tackling the disease effectively.
Our primary goal was to assess the median progression-free survival (mPFS), alongside secondary outcomes that included the one- and two-year progression-free survival rates, as well as the occurrence of adverse events related to treatments. The results were promising: patients who received iodine treatment experienced longer survival times and reported fewer adverse effects compared to those undergoing traditional RT.
The findings suggest that Iodine-125 seed implantation could be a more advantageous option for treating this specific type of lung cancer, offering a precision approach that minimizes damage to healthy lung tissue. This less invasive method could provide patients with a better quality of life while still tackling the disease effectively.
Read More
9
Iodine treatment aids recurrent cancer
We observed a compelling case where a biodegradable hydrogel spacer was used alongside iodine-125 brachytherapy to treat recurrent prostate cancer. This innovative approach involved placing the spacer to create space between the prostate and the rectum, which significantly reduced radiation exposure to healthy tissues during the treatment.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Following initial external beam radiotherapy in 2015, the patient showed signs of local recurrence by 2022. To address this, the treatment plan included not just the iodine-125 brachytherapy but also the hydrogel spacer, which was placed in January 2024 just before the radiation treatment. Six months later, we noted a remarkable drop in the patient’s prostate-specific antigen (PSA) levels, indicating a positive response to the treatment.
This case showcases the potential benefits of using iodine treatment in combination with advanced techniques like hydrogel spacers. The results suggest that this method not only improves the effectiveness of therapy but also ensures higher safety by protecting adjacent tissues from unnecessary radiation damage. Overall, we find this integration of technology highly beneficial for managing recurrent cancer challenges.
Read More
9
Iodine peptides show cancer treatment promise
We explored the effectiveness of iodine-labeled peptides, specifically I-TFMP-Y4 and I-Caerin 1.1, in treating hepatocellular carcinoma, a common type of liver cancer. Our study included in vitro experiments where we assessed how these peptides affected the growth of liver cancer cells, as well as in vivo tests using a hormone-treated nude mouse model.
We found that both I-Caerin 1.1 and I-TFMP-Y4 were effective at inhibiting the proliferation of Hepg2 cells, which are a model for liver cancer. Interestingly, while I-Caerin 1.1 showed a significant impact, we observed that TFMP-Y4 alone did not inhibit the liver cancer cells, suggesting its effectiveness might rely on its pairing with Iodine.
Additionally, we noted that I-TFMP-Y4 has the potential to lessen adverse reactions during treatment compared to I-Caerin 1.1. This finding is particularly important as it may improve the safety profile of the treatment, making it more acceptable for patients undergoing therapy.
We found that both I-Caerin 1.1 and I-TFMP-Y4 were effective at inhibiting the proliferation of Hepg2 cells, which are a model for liver cancer. Interestingly, while I-Caerin 1.1 showed a significant impact, we observed that TFMP-Y4 alone did not inhibit the liver cancer cells, suggesting its effectiveness might rely on its pairing with Iodine.
Additionally, we noted that I-TFMP-Y4 has the potential to lessen adverse reactions during treatment compared to I-Caerin 1.1. This finding is particularly important as it may improve the safety profile of the treatment, making it more acceptable for patients undergoing therapy.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 8 Reviews
7.7
- All Reviews
- Positive Reviews
- Negative Reviews
9
Supports immunity enhancement
This is one of the best manufacturers of vitamin D. It promotes muscle tone, increases immunity, supports thyroid function and normal blood clotting, and aids in restoring the protective sheaths around nerves. It also regulates blood pressure and heart rate while preventing cancer cell growth. I recommend taking it year-round at a dosage of 1000, ensuring sufficient levels in the body. Remember, vitamin D has a cumulative effect, so there's no fear of overdose when paired with vitamin K, which reduces liver strain.
Read More
7.5
Reduces cancer growth
Vitamin D helps the body absorb calcium and phosphorus, essential for bone growth. Besides its building function, it performs a protective role by decreasing cancer cell growth, aiding the immune system against infections, and lessening inflammation. It is also crucial for the normal functioning of the neuromuscular, endocrine, and immune systems.
Read More
7.5
Effective for cancer
I have been using this as part of my regimen for cancer treatment, and so far, everything is going well. My vitamin D levels have improved after years of consistent use, proving effective for my health regime.
Read More
7.5
Strong supplement choice
This product is excellent, incorporating K1, K2, and Vitamin D3, aiding calcium absorption while possessing anti-inflammatory properties. It has demonstrated a capacity to reduce cancer cell growth. K2 directs calcium to the bones, ensuring proper absorption, while K1 supports blood clotting and overall heart health.
Read More
7.5
Helpful for cancer history
I use this supplement due to previously low vitamin D levels, managing to boost it significantly. I have observed my levels rise through lab results, confirming its effectiveness. The inclusion of iodine and vitamin K offers added benefits, particularly vital for anyone with a cancer history.
Read More
Frequently Asked Questions
7.5
Effective for cancer
I have been using this as part of my regimen for cancer treatment, and so far, everything is going well. My vitamin D levels have improved after years of consistent use, proving effective for my health regime.
7.5
Strong supplement choice
This product is excellent, incorporating K1, K2, and Vitamin D3, aiding calcium absorption while possessing anti-inflammatory properties. It has demonstrated a capacity to reduce cancer cell growth. K2 directs calcium to the bones, ensuring proper absorption, while K1 supports blood clotting and overall heart health.
9
Supports immunity enhancement
This is one of the best manufacturers of vitamin D. It promotes muscle tone, increases immunity, supports thyroid function and normal blood clotting, and aids in restoring the protective sheaths around nerves. It also regulates blood pressure and heart rate while preventing cancer cell growth. I recommend taking it year-round at a dosage of 1000, ensuring sufficient levels in the body. Remember, vitamin D has a cumulative effect, so there's no fear of overdose when paired with vitamin K, which reduces liver strain.
7.5
Helpful for cancer history
I use this supplement due to previously low vitamin D levels, managing to boost it significantly. I have observed my levels rise through lab results, confirming its effectiveness. The inclusion of iodine and vitamin K offers added benefits, particularly vital for anyone with a cancer history.
7.5
Reduces cancer growth
Vitamin D helps the body absorb calcium and phosphorus, essential for bone growth. Besides its building function, it performs a protective role by decreasing cancer cell growth, aiding the immune system against infections, and lessening inflammation. It is also crucial for the normal functioning of the neuromuscular, endocrine, and immune systems.
7
We explored how vitamin D3 impacts cancer metabolism through an innovative chip-based solid-phase extraction mass spectrometry method. This approach allowed us to closely analyze the metabolic changes in both normal liver cells and cancer cells, providing a real-time view of how these processes work. With this technology, we could detect various metabolites at incredibly low concentrations, helping us form a clearer picture of cellular metabolism.
Our observations highlighted significant differences in metabolism between normal cells and cancerous ones, specifically noting increased glycolytic activity and higher lactate production in cancer cells. When we treated the cancer cells with 1,25-dihydroxyvitamin D3 (the active form of vitamin D3), we found that it suppressed glucose uptake and altered metabolic activity in one type of cancer cell, HCT116. This finding suggests that vitamin D3 could play a regulatory role in how cancer cells manage their energy and metabolize nutrients.
Overall, our study sheds light on the metabolic changes associated with cancer and points to vitamin D3 as a potential modulator of these processes. The insights gained could be valuable for developing new cancer therapies and understanding metabolic diseases better.
Our observations highlighted significant differences in metabolism between normal cells and cancerous ones, specifically noting increased glycolytic activity and higher lactate production in cancer cells. When we treated the cancer cells with 1,25-dihydroxyvitamin D3 (the active form of vitamin D3), we found that it suppressed glucose uptake and altered metabolic activity in one type of cancer cell, HCT116. This finding suggests that vitamin D3 could play a regulatory role in how cancer cells manage their energy and metabolize nutrients.
Overall, our study sheds light on the metabolic changes associated with cancer and points to vitamin D3 as a potential modulator of these processes. The insights gained could be valuable for developing new cancer therapies and understanding metabolic diseases better.
7
Vitamin D3 contributes to cancer treatment
We explored the potential of vitamin D3 as part of a treatment combination with curcumin, examining its effects on human osteosarcoma cells. The study involved using calcium phosphate materials loaded with both curcumin and vitamin D3, which were then tested in a specific 3D-printed format designed to promote bone health.
Our observations indicated that as part of this combination, vitamin D3 plays a supportive role. We found that using these loaded materials improved the survival of bone-forming cells (osteoblasts) over an 11-day period. Additionally, the combination treatment significantly increased new bone formation when compared to control groups.
However, it's important to note that the study's focus on the dual impact of curcumin and vitamin D3 limits our ability to assess the isolated effects of vitamin D3 alone. The results showed a decrease in the proliferation of osteosarcoma cells, highlighting the potential anti-cancer properties of the treatment combination. Yet, these findings suggest that while vitamin D3 contributes positively, more research is needed to fully understand its effectiveness on its own.
Our observations indicated that as part of this combination, vitamin D3 plays a supportive role. We found that using these loaded materials improved the survival of bone-forming cells (osteoblasts) over an 11-day period. Additionally, the combination treatment significantly increased new bone formation when compared to control groups.
However, it's important to note that the study's focus on the dual impact of curcumin and vitamin D3 limits our ability to assess the isolated effects of vitamin D3 alone. The results showed a decrease in the proliferation of osteosarcoma cells, highlighting the potential anti-cancer properties of the treatment combination. Yet, these findings suggest that while vitamin D3 contributes positively, more research is needed to fully understand its effectiveness on its own.
8
We delved into the intriguing relationship between vitamin D and colorectal cancer (CRC) to uncover how this nutrient might influence cancer development and treatment. The study involved measuring the serum levels of active vitamin D (1,25(OH)D) in different groups, including those with normal conditions, colorectal adenomas (CRA), and colorectal cancer (CRC).
Our findings highlighted a significant drop in vitamin D levels in CRC patients, with levels falling to 19.00 µg/mL compared to 42.99 µg/mL in normal individuals. Additionally, we conducted bioinformatics analysis to pinpoint genes linked to vitamin D and colorectal cancer, testing these using HCT116 and HT29 cell lines.
We observed that vitamin D can inhibit the growth and spread of colon cancer cells, leading to a reduction in the activity of certain cancer-promoting genes. Interestingly, our analysis also showed that a diagnostic model based on five key vitamin D-related genes exhibited high diagnostic efficiency. This reveals vitamin D's potential as a supportive approach for CRC diagnosis and treatment, offering hope for improved cancer management.
Our findings highlighted a significant drop in vitamin D levels in CRC patients, with levels falling to 19.00 µg/mL compared to 42.99 µg/mL in normal individuals. Additionally, we conducted bioinformatics analysis to pinpoint genes linked to vitamin D and colorectal cancer, testing these using HCT116 and HT29 cell lines.
We observed that vitamin D can inhibit the growth and spread of colon cancer cells, leading to a reduction in the activity of certain cancer-promoting genes. Interestingly, our analysis also showed that a diagnostic model based on five key vitamin D-related genes exhibited high diagnostic efficiency. This reveals vitamin D's potential as a supportive approach for CRC diagnosis and treatment, offering hope for improved cancer management.
8
We investigated the potential of vitamin D3, also known as cholecalciferol, in combating cancer while addressing concerns about its toxicity at higher doses. This study focused on enhancing the effectiveness of vitamin D3 through a clever method called liposomal encapsulation, which helps minimize side effects.
We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.
Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.
We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.
We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.
Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.
We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.
References
- Xu N, Lin H, Ding X, Wang P, Lin JM. Isotope tracing-assisted chip-based solid-phase extraction mass spectrometry for monitoring metabolic changes and vitamin D3 regulation in cells. Talanta. 2025;288:127754. 10.1016/j.talanta.2025.127754
- Jo Y, Kushram P, Bose S. Curcumin and vitamin D3 release from calcium phosphate enhances bone regeneration. Biomater Sci. 2025. 10.1039/d4bm01188k
- Ezcurra-Hualde M, Zalba S, Bella Á, Arrizabalaga L, Risson A, et al. Liposomal encapsulation of cholecalciferol mitigates toxicity and delays tumor growth. Front Immunol. 2025;16:1529007. 10.3389/fimmu.2025.1529007
- Wang L, Xu R, Wang M, Wang M, Su S, et al. Exploration and Identification of Vitamin D and Related Genes as Potential Biomarkers for Colorectal Tumors. Onco Targets Ther. 2025;18:129. 10.2147/OTT.S495066
- Evans H, Greenhough A, Perry L, Lasanta G, Gonzalez CM, et al. Hypoxia Compromises the Differentiation of Human Osteosarcoma Cells to CAR-R, a Hydroxylated Derivative of Lithocholic Acid and Potent Agonist of the Vitamin D Receptor. Int J Mol Sci. 2025;26. 10.3390/ijms26010365
- Kittaka A. Synthetic Studies on Vitamin D Derivatives with Diverse but Selective Biological Activities. Chem Pharm Bull (Tokyo). 2025;73:1. 10.1248/cpb.c24-00598
- He W, Lv W, Liu L, Gong Y, Song K, et al. Enhanced Antiglioma Effect by a Vitamin D3-Inserted Lipid Hybrid Neutrophil Membrane Biomimetic Multimodal Nanoplatform. ACS Nano. 2024;18:35559. 10.1021/acsnano.4c13470
- Almassri HF, Abdul Kadir A, Srour M, Foo LH. The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial. Nutrients. 2024;16. 10.3390/nu16223960
- Maturana-Ramiìrez A, Aitken-Saavedra J, Rojas-Zúñiga G, Rojas-Alcayaga G, Espinoza-Santander I, et al. Hypovitaminosis D in patients with oral squamous cell carcinoma: Is a risk factor of developing this neoplasia?. Med Oral Patol Oral Cir Bucal. 2025;30:e24. 10.4317/medoral.26692
- Almassri HF, Abdul Kadir A, Srour M, Foo LH. The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial. Clin Nutr ESPEN. 2025;65:64. 10.1016/j.clnesp.2024.11.014
- García-Martínez JM, Chocarro-Calvo A, Martínez-Useros J, Regueira-Acebedo N, Fernández-Aceñero MJ, et al. SIRT1 Mediates the Antagonism of Wnt/β-Catenin Pathway by Vitamin D in Colon Carcinoma Cells. Int J Biol Sci. 2024;20:5495. 10.7150/ijbs.95875
- Kuhlen M, Kunstreich M, Eilsberger F, Luster M, Redlich A. Pediatric differentiated thyroid carcinoma leading to fatal lung fibrosis. Eur Thyroid J. 2025;14. 10.1530/ETJ-24-0341
- Wang Y, Huang S, Huang R. Two or three weeks of thyroid hormone withdrawal before initial I therapy for patients with differentiated thyroid carcinoma?. BMC Cancer. 2025;25:370. 10.1186/s12885-024-13313-3
- Shan C, Xu S, Cai G, Li M, Wang T, et al. Clinical outcome and prognosis of differentiated thyroid carcinoma with distant metastasis. Nucl Med Commun. 2025. 10.1097/MNM.0000000000001965
- Zhang M, Yang Y, Xu Y, Wang J, Li S. Iodinated Copper-Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy. Pharmaceutics. 2025;17. 10.3390/pharmaceutics17020149
- Ttofi E, Kyriacou C, Leontiou T, Parpottas Y. A Method for Calculating Small Sizes of Volumes in Postsurgical Thyroid SPECT/CT Imaging. Life (Basel). 2025;15. 10.3390/life15020200
- Nappi C, Megna R, Zampella E, Volpe F, Piscopo L, et al. External validation of a predictive model for post-treatment persistent disease by I whole-body scintigraphy in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2025. 10.1007/s00259-025-07124-2
- Condello V, Marchettini C, Ihre-Lundgren C, Nilsson JN, Juhlin CC. Comprehensive Gene Expression Analysis in Papillary Thyroid Carcinoma Reveals a Transcriptional Profile Associated with Reduced Radioiodine Avidity. Endocr Pathol. 2025;36:4. 10.1007/s12022-025-09849-0
- Cao J, Li X, Liang H, Li Y, Zhao F, et al. The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis. Ann Nucl Med. 2025. 10.1007/s12149-025-02029-4
- Tao X, Liang L, Xu J, Xie L, Wen Q, et al. Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2025;17:278. 10.21037/jtd-24-1403
- Bayoumi NA, El-Shershaby HM, Darwish WM. Synthesis of iron oxide nanocrystals functionalized with hyaluronic acid and I-cetuximab for targeted combined (radio-photothermal) treatment of HepG2 cells. Int J Biol Macromol. 2025;305:140890. 10.1016/j.ijbiomac.2025.140890
- McGoron AJ, Garcia JM, Uluvar B, Gulec SA. Thyroid differentiation profile for differentiated thyroid cancer. Endocr Oncol. 2025;5:e240072. 10.1530/EO-24-0072
- Yang LG, Yang ZG, Zhang J, Fu YL. Effects of I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer. Am J Cancer Res. 2025;15:42. 10.62347/THJB4749
- Lazrek A, Finocchi Ghersi S, Petre A, Houabes S, Serre AA, et al. Case report of the first use of a hydrogel rectal spacer for prostate cancer reirradiation via LDR brachytherapy: applications and technical notes. Front Oncol. 2025;15:1494304. 10.3389/fonc.2025.1494304
- Adnan Z, Sabo E, Kassem S. Metastatic papillary thyroid carcinoma with internal jugular vein tumor thrombus - A case report and review of the literature. Front Endocrinol (Lausanne). 2025;16:1505800. 10.3389/fendo.2025.1505800
- Ding T, Ge X, Hao S, Wang Z, Zhang W, et al. Nomogram prediction model for overall survival of late-stage lung cancer patients undergoing iodine-125 particle implantation brachytherapy. J Contemp Brachytherapy. 2024;16:410. 10.5114/jcb.2024.146836
- Du J, Ren W, Liu W, Zhou Y, Li Y, et al. Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation. BMC Cancer. 2025;25:245. 10.1186/s12885-025-13666-3
